Alcon’s dry eye drug achieves primary endpoints in Phase III trials

Alcon’s dry eye drug achieves primary endpoints in Phase III trials

Submitted by admin on January 10, 2024 - 9:42am
Source: 
Clinical Trials Arena
News Tags: 
Alcon
dry eye disease
FDA
clinical trials
AR-15512
Headline: 
Alcon’s dry eye drug achieves primary endpoints in Phase III trials
snippet: 

Alcon plans to file for regulatory approval for its dry eye drug with the FDA in mid-2024 after pivotal efficacy and safety studies met the primary endpoints.

Do Not Allow Advertisers to Use My Personal information